双歧三联活菌联合美沙拉嗪治疗轻中度溃疡性结肠炎的临床效果

Clinical effect of bifid-triple viable combined with mesalazine in the treatment of mild and moderate ulcerative colitis

目的研究采用双歧三联活菌联合美沙拉嗪治疗轻中度溃疡性结肠炎的临床效果。方法选择我院2016年10月至2017年12月收治的轻中度溃疡性结肠炎患者80例,将其均分为对照组(40例,美沙拉嗪治疗)和观察组(40例,双歧三联活菌联合美沙拉嗪治疗),比较两组的临床治疗效果。结果观察组的治疗总有效率显著高于对照组(P<0.05);治疗后,两组患者的C反应蛋白(CRP)水平、红细胞沉降率(ESR)及结肠病变程度评分均显著降低,且观察组低于对照组(P<0.05);两组的不良反应总发生率比较,差异不显著(P>0.05)。结论采用双歧三联活菌联合美沙拉嗪治疗轻中度溃疡性结肠炎的治疗效果显著,其能有效改善患者的炎性因子水平及结肠病变程度,且安全性高,值得临床应用。

Objective To study the clinical effect of bifid-triple viable combined with mesalazine in the treatment of mild and moderate ulcerative colitis. Methods A total of 80 patients with mild and moderate ulcerative colitis in our hospital from October 2016 to December 2017 were selected and divided into control group（n=40, treated with mesalazine）and observation group（n =40, treated with bifid-triple viable combined with mesalazine）. The clinical effects of the two groups were compared. Results The total effective rate of treatment in the observation group was significantly higher than that of the control group（P〈0.05）. After treatment, the levels of C reactive protein（CRP）, erythrocyte sedimentation rate（ESR） and scores of colonic lesion degree significantly decreased in the two groups, and those of the observation group were significantly lower than the control group（P〈0.05）. There was no significant differences in the total incidences of adverse reactions between the two groups（P〈0.05）. Conclusion Bifid-triple viable combined with mesalazine in the treatment of mild and moderate ulcerative colitis has a significant effect. It can effectively improve the level of inflammatory factors and degree of colonic lesion, with high safety and it is worthy of clinical application.